Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02), Zacks reports. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The firm had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million.
Eton Pharmaceuticals Stock Performance
Shares of NASDAQ:ETON traded down $0.56 during trading on Friday, hitting $14.22. The company's stock had a trading volume of 223,652 shares, compared to its average volume of 159,507. The business has a 50 day moving average price of $15.58 and a two-hundred day moving average price of $11.54. The company has a market capitalization of $370.45 million, a PE ratio of -64.64 and a beta of 1.37. Eton Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $18.41.
Analyst Ratings Changes
Several analysts recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $33.00 target price on shares of Eton Pharmaceuticals in a report on Wednesday. B. Riley reiterated a "buy" rating and issued a $24.00 target price (up previously from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday. Finally, Craig Hallum lifted their target price on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday.
Check Out Our Latest Stock Report on ETON
Eton Pharmaceuticals Company Profile
(
Get Free Report)
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
Featured Stories
Before you consider Eton Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.
While Eton Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
